Prescription Drugs Selected for Affordability Review
On August 4, 2023, the Prescription Drug Affordability Board (PDAB) selected 5 prescription drugs for affordability reviews:
The Board will begin conducting affordability reviews by analyzing the following information for each selected drug:
 Stakeholder Engagement
As affordability reviews begin for these prescription drugs, there are multiple ways stakeholders may engage in the affordability review process. The linked Stakeholder Engagement Guide provides detailed information on:
Stakeholders are encouraged to revisit the Stakeholder Engagement Guide and the PDAB website regularly for updates on meeting times and Zoom links.
Upcoming PDAB Meeting
The next PDAB meeting will be held on September 15 at 10 am MT. During the meeting, the Board will hold a rulemaking hearing to amend current rules to align with the statutory changes resulting from HB 23-1225. To provide testimony on linked rule changes, please email dora_ins_pdab@state.co.us.
PDAAC Updates and Upcoming Meeting
The Prescription Drug Affordability Advisory Council (PDAAC) has a new member: the Board voted on August 4 to appoint Leah Lindahl to fill the open position representing wholesalers.
The next scheduled PDAAC meeting will be held on October 12 at 9 am MT. This schedule may change to allow the PDAAC to meet sooner than October 12.
Stay Connected
Stakeholders are encouraged to visit the website regularly to stay informed of all upcoming meetings. To receive PDAB and PDAAC updates directly in your inbox, click here. To subscribe, you will need to enter your email and then choose Updates From Divisions > Division of Insurance > Division of Insurance Prescription Drug Affordability Board.
Please do not reply to this email as your response will not be read or forwarded.
|
